CRISPR Therapeutics AG is at the forefront of gene editing, pioneering treatments for serious diseases through its CRISPR/Cas9 technology. This innovative approach allows for precise DNA modifications, offering hope in areas like hemoglobinopathies, immune-oncology, autoimmune diseases, and type 1 diabetes. Its leading therapy, CASGEVY, aims to transform care for patients with severe blood disorders through gene-edited cell therapy. Additionally, the company is developing cutting-edge CAR T cell therapies and in vivo gene editing solutions, working in strategic partnerships to advance its mission of curing complex diseases.
The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug…
Most asset managers try to track the market. Through ARK Investment, Cathie Wood is trying to get ahead of the market’s best ideas by identifying disruptive innovation early, even when the underlying…
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots…
What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible? The personalized biotech…
CRISPR Therapeutics (NASDAQ:CRSP | CRSP Price Prediction) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday…
Joel South While insider buying has been slow lately, there have been some notable, large purchases at a couple of biotech companies, and e-commerce company.
Insiders have become bearish. In fact, according to MarketWatch, “Corporate insiders have taken a sharply pessimistic turn – selling their companies’ shares at the fastest rate in at least a decade.” Plus,…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
Pfizer (NYSE:PFE | PFE Price Prediction) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster…
The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month. The tech sector has been the driving force for the stock market’s gains…
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT | WMT Price Prediction)…
Cathie Wood is the founder and CEO of Ark Invest, an asset management firm focusing on disruptive innovation, with approximately $14 billion in assets across six actively managed ETFs, two index ETFs,…
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery process is…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re investing…
